Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 7/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365441 | 0.93 | ATR (0.48) | HDAC2HDAC1HDAC3ABL1ATR | |
| SCHEMBL19365606 | 0.89 | ATR (0.48) | HDAC2HDAC1HDAC3ABL1ATR | |
| SCHEMBL19670630 | 0.88 | HDAC1 (0.40) | HDAC2HDAC1HDAC3ABL1GSK3B | |
| SCHEMBL19365567 | 0.88 | HDAC1 (0.43) | HDAC2HDAC1HDAC3ABL1ATR | |
| SCHEMBL19365604 | 0.87 | HDAC1 (0.46) | HDAC2HDAC1HDAC3ABL1ATR | |
| SCHEMBL19706219 | 0.87 | HDAC3 (0.38) | HDAC2HDAC1HDAC3ABL1SIRT2 | |
| SCHEMBL19670340 | 0.87 | HDAC2 (0.38) | HDAC2HDAC1HDAC3ABL1CYP3A4 | |
| SCHEMBL19365297 | 0.87 | HDAC2 (0.41) | HDAC2HDAC1HDAC3ATRSIRT2 | |
| SCHEMBL19365461 | 0.87 | HDAC1 (0.39) | HDAC2HDAC1HDAC3PIM3GSK3B | |
| SCHEMBL19670617 | 0.85 | MAPK1 (0.42) | HDAC2HDAC1HDAC3ABL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HDAC2 50/4885HDAC1 71/4885HDAC3 70/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | HDAC2 50/4885HDAC1 71/4885HDAC3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.